Vaccines against cervical cancer.
OBJECTIVE
The purpose of this review is to give an overview of recent developments relating to human papillomavirus vaccines and their effect on cervical cancer. Original research publications from the last year (2007) have been reviewed and summarized to present an up to date synopsis of relevant trials, and the impact they will have on clinical practice. Comparisons of the two vaccines on the market are made, and details of each are given. The effect of vaccination on men and those in the developing world is explored.


RESULTS
Recent findings include results of the Females United to Unilaterally Reduce Endo/Ectocervical Disease II (FUTURE II) and PApilloma TRIal against Cancer In young Adults (PATRICIA) trials that show a significant reduction in human papillomavirus-associated anogenital disease with both quadrivalent and bivalent vaccines. The effect is greatest in women who are not yet exposed to the human papillomavirus. The international community recognizes the potential impact of this, particularly in the developing world, and strategies are being developed to try and deliver care effectively.


CONCLUSIONS
In summary, research published in the last year has continued the initial optimistic outlook for human papillomavirus vaccination and it is likely that its effect on cervical cancer will be as promising as initially appeared.
Rogers
Linda J
LJ
Pan-Birmingham Gynaecological Oncology Centre, City Hospital, Birmingham, UK. linda.rogers@swbh.nhs.uk
Eva
Lois J
LJ
Luesley
David Michael
DM
D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control* / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination
D053918:Papillomavirus Vaccines